

February 11, 2020

To: Senate Health Care Committee

Senator Laurie Monnes-Anderson, Chair Senator Dennis Linthicum, Vice Chair

Re: SB 1535 Information Pharmaceutical Supply Chain – SUPPORT

I am writing today on behalf of the National Multiple Sclerosis Society (the Society) Oregon Chapter, in support of SB 1535 Information Pharmaceutical Supply Chain.

Multiple Sclerosis (MS) is an unpredictable, often disabling disease of the central nervous system. MS interrupts the flow of information within the brain and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. There is currently no cure for MS and since the disease is not fatal, a person can live with the disease their entire life. Research shows that early and ongoing treatment with a disease-modifying therapy (DMT) is the best way to slow the course of disease and disability from relapsing forms of MS.

The Society is supportive of overall efforts to bring more transparency and understanding to the costs that contribute to drug manufacturers pricing decisions. The Society supports transparency in R&D costs, marketing & advertising, profits, WAC costs, and total transparency around manufacturer patient assistance programs. Specific to SB 1535, we see pg. 4 lines 34-39 "cumulative increase" and "10% higher" and are pleased to see based on our reading, if the price at anytime during the previous calendar year was 10% higher or more than at any other time during the previous calendar year, then this would fall under the reporting requirements. In Sec. 5 the inclusion of two consumer advocates will ensure patient voices continue to be heard on the task force and we applaud this inclusion. Lastly, the extension to 2022 will allow the task force to complete its charge.

Thank you on behalf of all Oregonians living with MS.

Regards,

Seth Greiner

Sr. Mgr. Advocacy
National MS Society
seth.greiner@nmss.org

720-369-1665